Replimune Group, Inc.
REPLNASDAQHealthcareBiotechnology
Previous close
$14.77
+$0.72 · +5.12%
REPL company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
29
Expensive
Momentum
57
Neutral
Sentiment
36
Bearish
Risk resilience
54
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteReplimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Sushil Patel
- Listed since
- Jul 20, 2018
- Employees
- 465
Market position
Day range
Current $14.77
52-week range
Current $14.77
- Open
- $13.86
- Previous close
- $14.05
- Volume
- 2.97M
- 0.46× average
- Average volume
- 6.44M
- Average daily volume
- Market cap
- 1.24B USD
- Beta
- 0.9
- Market reference 1
- 50-day average
- $11.1625
- +32.32% above average
- 200-day average
- $8.2605
- +78.80% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 612.51M USD
- EV / EBITDA
- -2.03×
- Earnings yield
- -44.22%
- Free cash flow yield
- -40.08%
Profitability & efficiency
- Return on equity
- -188.94%
- Return on assets
- -94.45%
- Return on invested capital
- -114.79%
Financial health
- Current ratio
- 4.79×
- Altman Z-score
- -5.36
- Piotroski F-score
- 1 of 9
Earnings
- EPS beat rate
- 36%
- 4 beats, 7 misses, 0 met estimates
- Average EPS surprise
- -0.43%
- 11 comparable reports
- Latest EPS result
- -0.72
- Estimate -0.69 · Miss by 3.75%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$18.67
26.40% upsideRating distribution
15 ratingsRecent analyst actions
REPL peers
ETFs holding REPL
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P Biotech ETFXBI40.51M0.36%11.39B USD0.35%$165.73+1.44%
iShares Russell 2000 ETFIWM28.68M0.04%81.62B USD0.19%$299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI22.09M0.00%2.3T USD0.03%$378.24+0.44%
iShares Russell 2000 Value ETFIWN10.43M0.07%14.66B USD0.24%$224.81+0.45%
Vanguard Extended Market ETFVXF9.67M0.01%93.7B USD0.05%$245.53+0.82%
iShares Biotechnology ETFIBB8.09M0.08%10.75B USD0.44%$213.56+1.29%
Invesco Dorsey Wright Healthcare Momentum ETFPTH6.1M2.26%273.34M USD0.72%$62.9761+1.53%
Schwab U.S. Small-Cap ETFSCHA5M0.02%23.1B USD0.03%$34.83+0.52%State Street SPDR S&P Biotech ETFXBI- Market value
- 40.51M
- Weight
- 0.36%
- AUM
- 11.39B USD
- Expense ratio
- 0.35%
- Price / 1D
- $165.73+1.44%
iShares Russell 2000 ETFIWM- Market value
- 28.68M
- Weight
- 0.04%
- AUM
- 81.62B USD
- Expense ratio
- 0.19%
- Price / 1D
- $299.96+0.77%
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 22.09M
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $378.24+0.44%
iShares Russell 2000 Value ETFIWN- Market value
- 10.43M
- Weight
- 0.07%
- AUM
- 14.66B USD
- Expense ratio
- 0.24%
- Price / 1D
- $224.81+0.45%
Vanguard Extended Market ETFVXF- Market value
- 9.67M
- Weight
- 0.01%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $245.53+0.82%
iShares Biotechnology ETFIBB- Market value
- 8.09M
- Weight
- 0.08%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Invesco Dorsey Wright Healthcare Momentum ETFPTH- Market value
- 6.1M
- Weight
- 2.26%
- AUM
- 273.34M USD
- Expense ratio
- 0.72%
- Price / 1D
- $62.9761+1.53%
Schwab U.S. Small-Cap ETFSCHA- Market value
- 5M
- Weight
- 0.02%
- AUM
- 23.1B USD
- Expense ratio
- 0.03%
- Price / 1D
- $34.83+0.52%
Continue in GoAI
Research REPLresearch.disclaimer